Levels of anti-insulin antibodies in diabetic retinopathy patients: an observational cross-sectional study

References

• Chatziralli IP. The role of glycemic control and variability in diabetic retinopathy. Diab. Ther. 9(1), 431–434 (2018).
   PubMed Web of Science ®Google Scholar
• Kropp M, Golubnitschaja O, Mazurakova A et al. Diabetic retinopathy as the leading cause of blindness and early predictor of cascading complications-risks and mitigation. EPMA J. 14(1), 21–42 (2023).
   PubMed Web of Science ®Google Scholar
• Teo ZL, Tham Y-C, Yu M et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology 128(11), 1580–1591 (2021).
   PubMed Web of Science ®Google Scholar
• Al-Kharashi AS. Role of oxidative stress, inflammation, hypoxia and angiogenesis in the development of diabetic retinopathy. Saudi J. Ophthalmol. 32(4), 318–323 (2018).
   PubMed Web of Science ®Google Scholar
• Capitão M, Soares R. Angiogenesis and inflammation crosstalk in diabetic retinopathy. J. Cell. Biochem. 117(11), 2443–2453 (2016).
   PubMed Web of Science ®Google Scholar
• Arabi A, Tadayoni R, Ahmadieh H, Shahraki T, Nikkhah H. Update on management of nonproliferative diabetic retinopathy without diabetic macular edema; is there a paradigm shift? J. Ophth. Vision Res. 17(1), 108 (2022).
   PubMed Web of Science ®Google Scholar
• Alli-Shaik A, Qiu B, Lai SL et al. System-wide vitreous proteome dissection reveals impaired sheddase activity in diabetic retinopathy. Theranostics 12(15), 6682 (2022).
   PubMed Web of Science ®Google Scholar
• Saeedi P, Petersohn I, Salpea P et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. Diabetes Res. Clin. Pract. 157, 107843 (2019).
   PubMed Web of Science ®Google Scholar
• Burgess P, Maccormick I, Harding S, Bastawrous A, Beare N, Garner P. Epidemiology of diabetic retinopathy and maculopathy in Africa: a systematic review. Diabet. Med. 30(4), 399–412 (2013).
   PubMed Web of Science ®Google Scholar
• Amissah-Arthur KN, Mensah E. The past, present and future management of sickle cell retinopathy within an African context. Eye (Lond) 32(8), 1304–1314 (2018).
   PubMed Web of Science ®Google Scholar
• Mensah-Debrah A, Amissah Arthur KN, Kumah DB, Akuffo KO, Osei Duah I, Bascaran C. Situational analysis of diabetic retinopathy treatment Services in Ghana. BMC Health Serv. Res. 21(1), 1–12 (2021).
   PubMed Web of Science ®Google Scholar
• Akrofi B, Tetteh J, Amissah-Arthur KN, Buxton EN, Yawson A. Utilization of eye health services and diabetic retinopathy: a cross-sectional study among persons living with diabetes visiting a tertiary eye care facility in Ghana. BMC Health Serv. Res. 21(1), 1–11 (2021).
   PubMed Web of Science ®Google Scholar
• Khoo K, Man RE, Rees G, Gupta P, Lamoureux EL, Fenwick EK. The relationship between diabetic retinopathy and psychosocial functioning: a systematic review. Qual. Life Res. 28, 2017–2039 (2019).
   PubMed Web of Science ®Google Scholar
• Wredling R, Lins P, Adamson U. Prevalence of anti-insulin antibodies and its relation to severe hypoglycemia in insulin-treated diabetic patients. Scandinavian J. Clin. Lab. Invest. 50(5), 551–557 (1990).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Segade S, Camina M, Carnero A et al. High serum IgA concentrations in patients with diabetes mellitus: agewise distribution and relation to chronic complications. Clin. Chem. 42(7), 1064–1067 (1996).
   PubMed Web of Science ®Google Scholar
• Kanauchi M, Kawano T, Dohi K. Serum IgA levels in patients with diabetic nephropathy and IgA nephropathy superimposed on diabetes mellitus. Diabetes Res. Clin. Pract. 48(2), 113–118 (2000).
   PubMed Web of Science ®Google Scholar
• Bortolotti D, Mothe-Satney I, Ferrari P et al. Spontaneous hypoglycemia in the presence of both anti-insulin antibody and anti-insulin receptor antibody. Diab. Metab. 32(6), 598–603 (2006).
   PubMed Web of Science ®Google Scholar
• Crouthamel M-C, Kahana JA, Korenchuk S et al. Mechanism and management of AKT inhibitor-induced hyperglycemia. Clin. Cancer Res. 15(1), 217–225 (2009).
   PubMed Web of Science ®Google Scholar
• Lotfy M, Adeghate J, Kalasz H, Singh J, Adeghate E. Chronic complications of diabetes mellitus: a mini review. Curr. Diabetes Rev. 13(1), 3–10 (2017).
   PubMed Web of Science ®Google Scholar
• Park-Windhol C, D'amore PA. Disorders of vascular permeability. Ann. Rev. Pathol.: Mechanisms Dis. 11, 251–281 (2016).
   PubMed Web of Science ®Google Scholar
• Committee ADaPP, Committee: ADaPP. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care 45(Suppl. 1), S17–S38 (2022).
   PubMedGoogle Scholar
• Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and Type 2 diabetes. Diabetes Res. Clin. Pract. 105(2), 141–150 (2014).
   PubMed Web of Science ®Google Scholar
• Su C-T, Lin Y-C. Hyperinsulinemic hypoglycemia associated with insulin antibodies caused by exogenous insulin analog. Endocrinol. Diab. Metab. Case Reports 2016(1), 16-0079 (2016).
   Google Scholar
• Ejaz S, Chekarova I, Ejaz A, Sohail A, Lim CW. Importance of pericytes and mechanisms of pericyte loss during diabetic retinopathy. Diab. Obes. Metab. 10(1), 53–63 (2008).
   PubMed Web of Science ®Google Scholar
• Hammes H-P, Lin J, Renner O et al. Pericytes and the pathogenesis of diabetic retinopathy. Diabetes 51(10), 3107–3112 (2002).
   PubMed Web of Science ®Google Scholar
• Heng L, Comyn O, Peto T et al. Diabetic retinopathy: pathogenesis, clinical grading, management and future developments. Diabet. Med. 30(6), 640–650 (2013).
   PubMed Web of Science ®Google Scholar
• Eshaq RS, Aldalati AM, Alexander JS, Harris NR. Diabetic retinopathy: breaking the barrier. Pathophysiology 24(4), 229–241 (2017).
   PubMedGoogle Scholar
• Akinci B, Yener S, Bayraktar F, Yesil S. Allergic reactions to human insulin: a review of current knowledge and treatment options. Endocrine 37, 33–39 (2010).
   PubMed Web of Science ®Google Scholar
• Ahsan H. Diabetic retinopathy-biomolecules and multiple pathophysiology. Diab. Metab. Synd. Clin. Res. Rev. 9(1), 51–54 (2015).
   PubMed Web of Science ®Google Scholar
• Mathias CB, Mcaleer JP, Szollosi DE. Inflammatory diseases of the gastrointestinal tract and pharmacological treatments. Pharmacol. Immunotherap. Drugs 175–205 (2020).
   Google Scholar
• Schoenberger SD, Kim SJ, Sheng J, Rezaei KA, Lalezary M, Cherney E. Increased prostaglandin E2 (PGE2) levels in proliferative diabetic retinopathy, and correlation with VEGF and inflammatory cytokines. Investig. Ophthalmol. Vis. Sci. 53(9), 5906–5911 (2012).
   PubMed Web of Science ®Google Scholar
• Pini A, Verta R, Grange C, Gurrieri M, Rosa AC. Histamine and diabetic nephropathy: an up-to-date overview. Clin. Sci. 133(1), 41–54 (2019).
   Web of Science ®Google Scholar
• Zhu J, Han J, Liu L et al. Clinical expert consensus on the assessment and protection of pancreatic islet β-cell function in Type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 197, 110568 (2023).
   PubMed Web of Science ®Google Scholar
• Shen Y, Song X, Ren Y. Insulin autoimmune syndrome induced by exogenous insulin injection: a four-case series. BMC Endocr. Disord. 19(1), 1–6 (2019).
   PubMed Web of Science ®Google Scholar
• Asare-Anane H, Ofori E, Agyemang Y et al. Obesity and testosterone levels in Ghanaian men with Type 2 diabetes. Clin. Diab. 32(2), 61–65 (2014).
   PubMedGoogle Scholar
• Ofori EK, Buabeng A, Amanquah SD et al. Effect of circulating ceramides on adiposity and insulin resistance in patients with Type 2 diabetes: an observational cross-sectional study. Endocrinol. Diab. Metab. 6(3), e418 (2023).
   PubMedGoogle Scholar
• Niswender K. Diabetes and obesity: therapeutic targeting and risk reduction-a complex interplay. Diabet. Obes. Metabol. 12(4), 267–287 (2010).
   PubMed Web of Science ®Google Scholar
• Rana J, Nieuwdorp M, Jukema J, Kastelein J. Cardiovascular metabolic syndrome-an interplay of, obesity, inflammation, diabetes and coronary heart disease. Diabet. Obes. Metabol. 9(3), 218–232 (2007).
   PubMed Web of Science ®Google Scholar
• Kamboj A, Lause M, Kumar P. Ophthalmic manifestations of endocrine disorders-endocrinology and the eye. Translat. Pediat. 6(4), 286 (2017).
   PubMed Web of Science ®Google Scholar
• Chawla A, Chawla R, Jaggi S. Microvasular and macrovascular complications in diabetes mellitus: distinct or continuum? Indian J. Endocrinol. Metabol. 20(4), 546 (2016).
   PubMedGoogle Scholar
• Kohner EM, Aldington SJ, Stratton IM et al. United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. Arch. Ophthalmol. 116(3), 297–303 (1998).
   PubMedGoogle Scholar
• King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for Type 2 diabetes. Br. J. Clin. Pharmacol. 48(5), 643 (1999).
   PubMed Web of Science ®Google Scholar
• Zhang X, Bao S, Hambly BD, Gillies MC. Vascular endothelial growth factor-A: a multifunctional molecular player in diabetic retinopathy. Inter. J. Biochem. Cell Biol. 41(12), 2368–2371 (2009).
   PubMed Web of Science ®Google Scholar
• Artunc F, Schleicher E, Weigert C, Fritsche A, Stefan N, Häring H-U. The impact of insulin resistance on the kidney and vasculature. Nat. Rev. Nephrol. 12(12), 721–737 (2016).
   PubMed Web of Science ®Google Scholar